Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease

Contemporary Clinical Trials

Volumn 37, Issue 2, 2014, Pages 301-311

  Scorletti, E ^a   Bhatia, L ^a,b   McCormick, K G ^a   Clough, G F ^a   Nash, K ^c   Calder, P C ^a,b   Byrne, C D ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; MRS: magnetic resonance spectroscopy; NAFLD: Non alcoholic fatty liver disease; Purified long chain omega 3 fatty acids

Indexed keywords

BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OLIVE OIL; OMEGA 3 ACID ETHYL ESTER; DRUG COMBINATION; OMEGA 3 FATTY ACID; VEGETABLE OIL;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; CARDIOMETABOLIC RISK; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; GAS CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; DIET; DIET SUPPLEMENTATION; DRUG COMBINATION; EXERCISE; FITNESS; HEART FUNCTION TEST; LIVER; LIVER CIRRHOSIS; METHODOLOGY; MORPHOMETRICS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BODY WEIGHTS AND MEASURES; DIET; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; EXERCISE; FATTY ACIDS, OMEGA-3; HEART FUNCTION TESTS; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSICAL FITNESS; PLANT OILS; RESEARCH DESIGN; RISK FACTORS;

EID: 84896770640     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.02.002     Document Type: Article

References (57)

1. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology Jun 2012, 142(7):1592-1609.
2. Byrne C.D. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc May 2013, 14:1-8.
3. Targher G., Byrne C.D. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab Feb 2013, 98(2):483-495.
4. Lam B., Younossi Z.M. Treatment options for nonalcoholic fatty liver disease. Ther Adv Gastroenterol Mar 2010, 3(2):121-137.
5. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology Jul 2008, 135(1):100-110.
6. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med May 6, 2010, 362(18):1675-1685.
7. Lomonaco R., Ortiz-Lopez C., Orsak B., Webb A., Hardies J., Darland C., et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology May 2012, 55(5):1389-1397.
8. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol Apr 2012, 56(4):944-951.
9. Food U.S., Administration Drug FDA briefing document: joint meeting of the Endocrinologic and Metabolic Drug Advisory Committee and the Drug Safety and Risk Management Committee 2010.
10. Murphy C.E., Rodgers P.T. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother Dec 2007, 41(12):2014-2018.
11. Dietrich M., Jacques P.F., Pencina M.J., Lanier K., Keyes M.J., Kaur G., et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role?. Atherosclerosis Aug 2009, 205(2):549-553.
12. Pachikian B.D., Neyrinck A.M., Cani P.D., Portois L., Deldicque L., De Backer F.C., et al. Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol 2008, 8:21.
13. Mirmiran P., Hosseinpour-Niazi S., Naderi Z., Bahadoran Z., Sadeghi M., Azizi F. Association between interaction and ratio of omega-3 and omega-6 polyunsaturated fatty acid and the metabolic syndrome in adults. Nutrition Sep 2012, 28(9):856-863.
14. Simopoulos A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) Jun 2008, 233(6):674-688.
15. Marsman H.A., Heger M., Kloek J.J., Nienhuis S.L., van Werven J.R., Nederveen A.J., et al. Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model. J Gastroenterol Hepatol Feb 2011, 26(2):356-363.
16. Hatzitolios A., Savopoulos C., Lazaraki G., Sidiropoulos I., Haritanti P., Lefkopoulos A., et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol Jul 2004, 23(4):131-134.
17. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L., Bedogni G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther Apr 15, 2006, 23(8):1143-1151.
18. Vega G.L., Chandalia M., Szczepaniak L.S., Grundy S.M. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med Jun 2008, 56(5):780-785.
19. Spadaro L., Magliocco O., Spampinato D., Piro S., Oliveri C., Alagona C., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis Mar 2008, 40(3):194-199.
20. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol Apr 2008, 42(4):413-418.
21. Zhu F.S., Liu S., Chen X.M., Huang Z.G., Zhang D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol Nov 7, 2008, 14(41):6395-6400.
22. Cussons A.J., Watts G.F., Mori T.A., Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab Oct 2009, 94(10):3842-3848.
23. Nobili V., Bedogni G., Alisi A., Pietrobattista A., Rise P., Galli C., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child Apr 2011, 96(4):350-353.
24. Robinson S., Syddall H., Jameson K., Batelaan S., Martin H., Dennison E.M., et al. Current patterns of diet in community-dwelling older men and women: results from the Hertfordshire Cohort Study. Age Ageing Sep 2009, 38(5):594-599.
25. Guha I.N., Parkes J., Roderick P., Chattopadhyay D., Cross R., Harris S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology Feb 2008, 47(2):455-460.
26. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology Apr 2007, 45(4):846-854.
27. Pearce S.G., Thosani N.C., Pan J.J. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013, 1(1):7.
28. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology Dec 2004, 127(6):1704-1713.
29. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology Dec 1999, 30(6):1356-1362.
30. Holt H.B., Wild S.H., Wareham N., Ekelund U., Umpleby M., Shojaee-Moradie F., et al. Differential effects of fatness, fitness and physical activity energy expenditure on whole-body, liver and fat insulin sensitivity. Diabetologia Aug 2007, 50(8):1698-1706.
31. Kleiner D.E., Brunt E.M., Van N.M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology Jun 2005, 41(6):1313-1321.
32. Duffy J.C. Alcohol consumption and all-cause mortality. Int J Epidemiol Feb 1995, 24(1):100-105.
33. Kloppenburg W.D., Wolthers B.G., Stellaard F., Elzinga H., Tepper T., de Jong P.E., et al. Determination of urea kinetics by isotope dilution with [13C]urea and gas chromatography-isotope ratio mass spectrometry (GC-IRMS) analysis. Clin Sci (Lond) Jul 1997, 93(1):73-80.
34. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation Oct 20, 2009, 120(16):1640-1645.
35. Elizondo A., Araya J., Rodrigo R., Signorini C., Sgherri C., Comporti M., et al. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol Res 2008, 41(1):59-68.
36. Barros K.V., Carvalho P.O., Cassulino A.P., Andrade I., West A.L., Miles E.A., et al. Fatty acids in plasma, white and red blood cells, and tissues after oral or intravenous administration of fish oil in rats. Clin Nutr Dec 2013, 32(6):993-998.
37. Elizondo A., Araya J., Rodrigo R., Poniachik J., Csendes A., Maluenda F., et al. Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity (Silver Spring) Jan 2007, 15(1):24-31.
38. Mignault D., St-Onge M., Karelis A.D., Allison D.B., Rabasa-Lhoret R. Evaluation of the Portable HealthWear Armband: a device to measure total daily energy expenditure in free-living type 2 diabetic individuals. Diabetes Care Jan 2005, 28(1):225-227.
39. Okin P.M., Devereux R.B., Nieminen M.S., Jern S., Oikarinen L., Viitasalo M., et al. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol Aug 2001, 38(2):514-520.
40. Levy D., Savage D.D., Garrison R.J., Anderson K.M., Kannel W.B., Castelli W.P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol Apr 15, 1987, 59(9):956-960.
41. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr Mar 2009, 10(2):165-193.
42. Greenberg N.L., Firstenberg M.S., Castro P.L., Main M., Travaglini A., Odabashian J.A., et al. Doppler-derived myocardial systolic strain rate is a strong index of left ventricular contractility. Circulation Jan 1, 2002, 105(1):99-105.
43. Gu C., Griffin M.J. Spatial summation of vibrotactile sensations at the foot. Med Eng Phys Aug 2013, 35(8):1221-1227.
44. Seah S.A., Griffin M.J. Normal values for thermotactile and vibrotactile thresholds in males and females. Int Arch Occup Environ Health Apr 2008, 81(5):535-543.
45. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation Jan 30, 2007, 115(4):459-467.
46. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med Jan 7, 1999, 340(1):14-22.
47. Stein J.H., Korcarz C.E., Hurst R.T., Lonn E., Kendall C.B., Mohler E.R., et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr Feb 2008, 21(2):93-111.
48. Wild S.H., Byrne C.D., Smith F.B., Lee A.J., Fowkes F.G. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care Mar 2006, 29(3):637-642.
49. Zimmet P., Magliano D., Matsuzawa Y., Alberti G., Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005, 12(6):295-300.
50. Browning L.M., Walker C.G., Mander A.P., West A.L., Madden J., Gambell J.M., et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr Oct 2012, 96(4):748-758.
51. Slee E.L., McLennan P.L., Owen A.J., Theiss M.L. Low dietary fish-oil threshold for myocardial membrane n-3 PUFA enrichment independent of n-6 PUFA intake in rats. J Lipid Res Jul 2010, 51(7):1841-1848.
52. Tikkanen M.J., Fayyad R., Faergeman O., Olsson A.G., Wun C.C., Laskey R., et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol Oct 9, 2013, 168(4):3846-3852.
53. Athyros V.G., Tziomalos K., Gossios T.D., Griva T., Anagnostis P., Kargiotis K., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet Dec 4, 2010, 376(9756):1916-1922.
54. Foster T., Budoff M.J., Saab S., Ahmadi N., Gordon C., Guerci A.D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol Jan 2011, 106(1):71-77.
55. Han K.H., Rha S.W., Kang H.J., Bae J.W., Choi B.J., Choi S.Y., et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol Jul 2012, 6(4):340-351.
56. Nseir W., Mograbi J., Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci Jul 2012, 57(7):1773-1781.
57. Scorletti E., Byrne C.D. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr Jul 17, 2013, 33:231-248.